Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-group pediatric pharmacokinetic and safety study of cefepime + enmetazobactam in complicated urinary tract infection
2022-001832-27Phase 2Active
- Sponsor
- Allecra Therapeutics
- Start
- Aug 2022
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cefepime and enmetazobactam in complicated urinary tract infection (cUTI) and acute pyelonephritis, sponsored by Allecra Therapeutics. Primary endpoints: Cmax, Tmax and 7 more. Started Aug 2022; status: active.
02
Drugs
cefepimeenmetazobactam
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritis
Beyond the preview
Go deeper on 2022-001832-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001832-27.